Symbols

BRKR

Bruker·NASDAQ

--(--)

BRKR fundamentals

BRKR Q4 2025 Earnings

Bruker (BRKR) released its earnings on Feb 12, 2026: revenue was 977.20M (YoY -0.24%), beat estimates; EPS was 0.59 (YoY -22.37%), missed estimates.

Revenue / YoY

977.20M

-0.24%

EPS / YoY

0.59

-22.37%

Report date

Feb 12, 2026

BRKR Earnings Call Summary for Q4,2025

Q4 2025 Results: Revenue flat YoY, EPS down 22% due to headwinds. Free cash flow $207M, highest on record.
2026 Outlook: 4%-5% reported revenue growth, 15%-17% EPS growth (23%-25% CER). 250-300 bps margin expansion via $140M+ cost savings.
Key Drivers: Biopharma and semiconductor metrology growth. ACA/GOV cautious but improving. 8% currency headwind on EPS.
Q1 2026 Challenges: Mid-single-digit organic decline vs. strong Q1 2025, with recovery in Q2+.
China Recovery: Q4 2025 bookings growth, FY2026 flat but biopharma/metrology pipeline positive.

Earnings

EPS

Revenue

Revenue & Expenses

BRKR has released its 2025 Q4 earnings report, with revenue of 977.20M, reflecting a YoY change of -0.24%, and net profit of 29.20M, showing a YoY change of 110.07%. The Sankey diagram below clearly presents BRKR's revenue sources and cost distribution.

Key Indicators

Bruker (BRKR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Bruker (BRKR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Bruker (BRKR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Bruker (BRKR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown